Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 4Breast 4Genitourinary 3Myeloid 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Plasma cell 1Other neoplasm 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Rectal Neoplasms 1Precancerous Conditions 1Colonic Neoplasms 1

Interventions

Whole-Body Irradiation 4Sulindac 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4fludarabine phosphate 3Selenium 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Cetuximab 3Biopsy 3Tacrolimus 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Polymerase Chain Reaction 2Oxycodone 2Mycophenolic Acid 2Melphalan 2Gene Expression Profiling 2Etoposide 2Darbepoetin alfa 2Cyclosporine 2Cyclophosphamide 2Cisplatin 2Busulfan 2Aspirin 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2vandetanib 1soybean oil, phospholipid emulsion 1ruxolitinib 1polyphenon E 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Atorvastatin × Other neoplasm × Clear all
NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
85 enrolled 10 charts
GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡